AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18580199 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted colectomy (LAC)
Number of subjects: 219
Study 18580199 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 219
Study 15743923 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cocaine (75 mg/70 kg) and codeine (60 mg/70 kg) administered subcutaneously and orally on alternating days for a total of three doses each during week 4.
Number of subjects: 10
Study 15743923 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cocaine (150 mg/70 kg) and codeine (120 mg/70 kg) administered during week 7.
Number of subjects: 10
Study 12218280 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supervised toothbrushing with toothpaste containing 1,000 ppm fluoride and 0.13% calcium glycerophosphate on school-days, combined with recommended daily home use.
Number of subjects: 534
Study 12218280 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention other than 6-monthly clinical examinations.
Number of subjects: 534
Study 10341404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 115
Study 10341404 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women (control)
Number of subjects: 115
Study 8563385 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized preadmission screening
Number of subjects: 0
Study 8563385 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection, intervention, and compliance factors
Number of subjects: 0
Study 2672807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg three times daily (n = 113)
Number of subjects: 222
Study 2672807 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 109)
Number of subjects: 222
Study 362875 — intervention group
Group type: EXPERIMENTAL
Intervention: Migen vaccine (6-injection course)
Number of subjects: 28
Study 362875 — intervention group
Group type: EXPERIMENTAL
Intervention: Migen vaccine (6-injection course + 6 maintenance injections)
Number of subjects: 28
Study 362875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 injections)
Number of subjects: 28
Study 362875 — intervention group
Group type: EXPERIMENTAL
Intervention: Migen vaccine (standard course of 6 injections)
Number of subjects: 28
Study 31871223 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening endoscopy
Number of subjects: 19981
Study 31871223 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 19981
Study 30755410 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 0
Study 30755410 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapies (patches and gum)
Number of subjects: 0
Study 28646590 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg) plus conventional therapy
Number of subjects: 33
Study 28646590 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus conventional therapy
Number of subjects: 33
Study 26113676 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (2.5 mg·day(-1) escalated to 10 mg·day(-1))
Number of subjects: 24
Study 24132082 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue impacted third molar
Number of subjects: 416
Study 24132082 — intervention group
Group type: EXPERIMENTAL
Intervention: Erupted third molar
Number of subjects: 416
Study 24132082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bony impacted third molar
Number of subjects: 416
Study 24132082 — intervention group
Group type: COMPARATOR
Intervention: Absent third molar
Number of subjects: 416
Study 21597124 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT); 2, 2-hour group sessions.
Number of subjects: 54
Study 21597124 — intervention group
Group type: COMPARATOR
Intervention: Education; 2, 2-hour group sessions.
Number of subjects: 54
Study 19954709 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐48 (7.5 g per day from 21 days before surgery to the day before surgery)
Number of subjects: 18
Study 19954709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TJ‐48)
Number of subjects: 18
Study 16912578 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly idursulfase (0.5 mg/kg)
Number of subjects: 96
Study 16912578 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-other-week idursulfase (0.5 mg/kg)
Number of subjects: 96
Study 16912578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 15549370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar extensor fatigue (fatigued to 60% of unfatigued maximum voluntary exertion force)
Number of subjects: 13
Study 15549370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue rate (fatigued over either 10 min or 90 min)
Number of subjects: 13
Study 11384805 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin 50 ml (n: 82)
Number of subjects: 250
Study 11384805 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (200/0.5) 500 ml (n: 85)
Number of subjects: 250
Study 11384805 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 ml 0.9% NaCl solution) (n: 83)
Number of subjects: 250
Study 9436574 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded oxygenator (group H, n = 11)
Number of subjects: 21
Study 9436574 — intervention group
Group type: COMPARATOR
Intervention: Nonbonded oxygenator (group C, n = 10)
Number of subjects: 21
Study 8299434 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to prescribed meal plan
Number of subjects: 623
Study 8299434 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusting food and/or insulin in response to hyperglycemia
Number of subjects: 623
Study 8299434 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-treating hypoglycemia
Number of subjects: 623
Study 8299434 — intervention group
Group type: EXPERIMENTAL
Intervention: Consuming extra snacks beyond the meal plan
Number of subjects: 623
Study 8299434 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusting insulin dose for meal size and content
Number of subjects: 623
Study 8299434 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent consumption of an evening snack
Number of subjects: 623
Study 8299434 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific diet-related behaviors
Number of subjects: 623
Study 3566457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 52
Study 3566457 — intervention group
Group type: COMPARATOR
Intervention: Unilateral ECT
Number of subjects: 52
Study 30157683 — intervention group
Group type: EXPERIMENTAL
Intervention: ERC1671 plus bevacizumab
Number of subjects: 0
Study 30157683 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus bevacizumab
Number of subjects: 0
Study 25875425 — intervention group
Group type: EXPERIMENTAL
Intervention: FMUD + PVPI (n=14)
Number of subjects: 28
Study 25875425 — intervention group
Group type: COMPARATOR
Intervention: FMUD + SS (n=14)
Number of subjects: 28
Study 24118850 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) with leuprorelin
Number of subjects: 39
Study 24118850 — intervention group
Group type: COMPARATOR
Intervention: Zometa
Number of subjects: 39
Study 22457045 — intervention group
Group type: COMPARATOR
Intervention: PRP
Number of subjects: 20
Study 22457045 — intervention group
Group type: EXPERIMENTAL
Intervention: PRPplus
Number of subjects: 20
Study 20163323 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0
Study 18458958 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (short-term use)
Number of subjects: 0
Study 18458958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (short-term use)
Number of subjects: 0
Study 18458958 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (short-term use)
Number of subjects: 0
Study 16385649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (200 mg daily for 2 weeks every 3 months)
Number of subjects: 50
Study 16385649 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (5 mg daily)
Number of subjects: 50
Study 14674833 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.16-androstadien-3-one (AND)
Number of subjects: 24
Study 14674833 — intervention group
Group type: EXPERIMENTAL
Intervention: l,3,5(10),16-estratetraen-3-ol (EST)
Number of subjects: 24
Study 14674833 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study 10620210 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) alone, N = 11
Number of subjects: 52
Study 10620210 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral calcitriol, N = 20
Number of subjects: 52
Study 10620210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intravenous calcitriol, N = 21
Number of subjects: 52
Study 8871414 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) treatment
Number of subjects: 150
Study 8871414 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Thoughts (AT) treatment
Number of subjects: 150
Study 8871414 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 150
Study 1514533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium supplementation (magnesium sulphate, 3 g before each CDDP administration)
Number of subjects: 41
Study 1514533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (magnesium pidolate, 2 g orally every 8 hours on days 2 to 21 of each CDDP course)
Number of subjects: 41
Study 1514533 — intervention group
Group type: COMPARATOR
Intervention: No magnesium supplementation (control group)
Number of subjects: 41
Study 6392354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 129
Study 6392354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 129
Study 6392354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 129
Study 6392354 — intervention group
Group type: COMPARATOR
Intervention: Codeine 90 mg
Number of subjects: 129
Study 6392354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 31542755 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 0
Study 31542755 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study 29653328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD) therapy
Number of subjects: 74
Study 27717298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 951
Study 27717298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 951
Study 25274719 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month SDT-based lifestyle intervention
Number of subjects: 221
Study 22905160 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamboo skirt intervention
Number of subjects: 200
Study 22905160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dhoincha skirt intervention
Number of subjects: 200
Study 22905160 — intervention group
Group type: EXPERIMENTAL
Intervention: Jute stick skirt intervention
Number of subjects: 200
Study 22905160 — intervention group
Group type: EXPERIMENTAL
Intervention: Polythene covering intervention
Number of subjects: 200
Study 22905160 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 21057561 — intervention group
Group type: COMPARATOR
Intervention: IL‐10‐1082 A/A homozygous genotype in benign brain tumors
Number of subjects: 45
Study 21057561 — intervention group
Group type: COMPARATOR
Intervention: IL‐6‐174 C/C homozygous genotype in benign brain tumors
Number of subjects: 45
Study 21057561 — intervention group
Group type: COMPARATOR
Intervention: IL‐6‐174 C/C homozygous genotype in malignant brain tumors
Number of subjects: 45
Study 21057561 — intervention group
Group type: COMPARATOR
Intervention: TNF‐a‐308 A/A homozygous genotype in malignant brain tumors
Number of subjects: 45
Study 21057561 — intervention group
Group type: COMPARATOR
Intervention: IL‐1Ra VNTR genotype polymorphism
Number of subjects: 45
Study 17689147 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat 200 mg three times a day
Number of subjects: 29
Study 17689147 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 29
Study 15451149 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (independent predictor of short-term mortality)
Number of subjects: 34
Study 15451149 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (independent predictor of long-term mortality)
Number of subjects: 34
Study 15451149 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and LV systolic dysfunction interaction
Number of subjects: 34
Study 11271867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 129
Study 11271867 — intervention group
Group type: COMPARATOR
Intervention: Counselling
Number of subjects: 129
Study 10021953 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administration (2 mg.kg‐1 at a rate of 200 mg.min‐1, followed by continuous infusion of 4 mg.kg‐1.hr‐1) during thoracic epidural anaesthesia
Number of subjects: 45
Study 10021953 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administration (2 mg.kg‐1 at a rate of 200 mg.min‐1, followed by continuous infusion of 4 mg.kg‐1.hr‐1) during lumbar epidural anaesthesia
Number of subjects: 45
Study 10021953 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving general anaesthesia alone
Number of subjects: 45
Study 7920873 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet modification training program (1 session per week for 8 weeks, including 20 min of walking)
Number of subjects: 44
Study 7920873 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet modification training program
Number of subjects: 44
Study 7920873 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 3171374 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine lozenges (10 mg)
Number of subjects: 0
Study 3171374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29543567 — intervention group
Group type: EXPERIMENTAL
Intervention: Edinburgh Pain Assessment and Management Tool (EPAT)
Number of subjects: 1921
Study 29543567 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1921
Study 29543567 — intervention group
Group type: EXPERIMENTAL
Intervention: EPAT (after excluding two centers that failed to implement)
Number of subjects: 1921
Study 29543567 — intervention group
Group type: EXPERIMENTAL
Intervention: EPAT
Number of subjects: 1921
Study 29543567 — intervention group
Group type: COMPARATOR
Intervention: EPAT and UC
Number of subjects: 1921
Study 27049915 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the ventral anterior limb of the internal capsule (vALIC)
Number of subjects: 25
Study 27049915 — intervention group
Group type: COMPARATOR
Intervention: Active DBS
Number of subjects: 25
Study 25432788 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg starting dose, oral once-daily)
Number of subjects: 0
Study 25432788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24645611 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic acid gel (PLA-G) used under the surface of the auxiliary operative wound in the treatment group.
Number of subjects: 68
Study 24645611 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention (nothing used).
Number of subjects: 68
Study 24645611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control).
Number of subjects: 68
Study 20064022 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum ointment applied 3 times a day for 16 days
Number of subjects: 144
Study 20064022 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied 3 times a day for 16 days
Number of subjects: 144
Study 20064022 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 144
Study 20064022 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum ointment
Number of subjects: 144
Study 20064022 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 144
Study 18562776 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke-leaf extract, 400 mg, 3 times a day for 5 weeks
Number of subjects: 22
Study 18562776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18562776 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke-leaf extract
Number of subjects: 22
Study 16999007 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride/sodium hexametaphosphate dentifrice (Crest Pro‐Health)
Number of subjects: 80
Study 16999007 — intervention group
Group type: COMPARATOR
Intervention: Triclosan/copolymer control dentifrice
Number of subjects: 80
Study 16999007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dentifrices
Number of subjects: 80
Study 12015788 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ER-lovastatin
Number of subjects: 9
Study 12015788 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ER-lovastatin
Number of subjects: 9
Study 12015788 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ER-lovastatin
Number of subjects: 9
Study 10495050 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the VIM nucleus of the thalamus
Number of subjects: 38
Study 10495050 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the VIM nucleus of the thalamus (stimulation 'on')
Number of subjects: 38
Study 10495050 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the VIM nucleus of the thalamus (stimulation 'off')
Number of subjects: 38
Study 8610317 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial B‐mode measurements of carotid IMT
Number of subjects: 237
Study 8610317 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAPS measurement protocol
Number of subjects: 237
Study 8610317 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up times of 2 years or more
Number of subjects: 237
Study 8610317 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up times of 6 years or more
Number of subjects: 237
Study 8610317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample sizes as low as 237
Number of subjects: 237
Study 1792411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamiphylline (1.2 g daily for 7 days)
Number of subjects: 15
Study 1792411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7303692 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopenthixol (Sordinol, Ciatyl) in small dosage
Number of subjects: 58
Study 7303692 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with clopenthixol)
Number of subjects: 58
Study 30865916 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 1
Study 30865916 — intervention group
Group type: COMPARATOR
Intervention: Unselected group of patients with UC (N=17)
Number of subjects: 1
Study 28376818 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes (nicotine-free and nicotine-inclusive) with behavioral support
Number of subjects: 0
Study 28376818 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT) with behavioral support
Number of subjects: 0
Study 26355674 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF)
Number of subjects: 833
Study 26355674 — intervention group
Group type: COMPARATOR
Intervention: dolutegravir (DTG) + abacavir/lamivudine (ABC/3TC)
Number of subjects: 833
Study 22943633 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry juice (BBJ)
Number of subjects: 0
Study 22943633 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen with BBJ
Number of subjects: 0
Study 22943633 — intervention group
Group type: COMPARATOR
Intervention: Grapefruit juice (GFJ)
Number of subjects: 0
Study 22943633 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (positive control)
Number of subjects: 0
Study 21272897 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (3 10-minute cycles of lower limb ischemia and reperfusion)
Number of subjects: 76
Study 21272897 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 76
Study 21272897 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 19531462 — intervention group
Group type: EXPERIMENTAL
Intervention: Health development program package (3-month duration)
Number of subjects: 125
Study 19531462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 125
Study 15888512 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acute tryptophan depletion (ATD)
Number of subjects: 20
Study 15888512 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acute tryptophan depletion (ATD)
Number of subjects: 20
Study 15888512 — intervention group
Group type: COMPARATOR
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 20
Study 12563237 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fluid management (16 to 18 mL x kg(‐1) x h(‐1))
Number of subjects: 56
Study 12563237 — intervention group
Group type: COMPARATOR
Intervention: Conservative fluid management (8 mL x kg(‐1) x h(‐1))
Number of subjects: 56
Study 10383528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg s.c.
Number of subjects: 16
Study 10383528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline control)
Number of subjects: 16
Study 8767949 — intervention group
Group type: EXPERIMENTAL
Intervention: Short incision (2.5 cm)
Number of subjects: 0
Study 8767949 — intervention group
Group type: EXPERIMENTAL
Intervention: Long incision (4.5 cm)
Number of subjects: 0
Study 8767949 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic release
Number of subjects: 0
Study 1916034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at 08.00 h
Number of subjects: 12
Study 1916034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at 22.00 h
Number of subjects: 12
Study 1916034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12